vs
Bioventus Inc.（BVS）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是Bioventus Inc.的1.2倍（$188.3M vs $157.9M），BRC Group Holdings, Inc.净利率更高（47.9% vs 9.3%，领先38.6%），Bioventus Inc.同比增速更快（2.8% vs -21.9%），过去两年Bioventus Inc.的营收复合增速更高（10.4% vs -15.4%）
Bioventus Inc.是一家全球化医疗技术企业，专注于骨科生物制剂领域，研发并商业化促进骨关节愈合、肌肉骨骼疼痛管理及再生护理的相关产品，服务全球多地的骨科临床医师、康复师及患者群体。
BVS vs RILY — 直观对比
营收规模更大
RILY
是对方的1.2倍
$157.9M
营收增速更快
BVS
高出24.6%
-21.9%
净利率更高
RILY
高出38.6%
9.3%
两年增速更快
BVS
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $157.9M | $188.3M |
| 净利润 | $14.8M | $90.3M |
| 毛利率 | 68.9% | 79.5% |
| 营业利润率 | 12.3% | 32.3% |
| 净利率 | 9.3% | 47.9% |
| 营收同比 | 2.8% | -21.9% |
| 净利润同比 | 3902.8% | 1710.8% |
| 每股收益（稀释后） | $0.21 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BVSRILY
| Q4 25 | $157.9M | $188.3M | ||
| Q3 25 | $138.7M | $215.3M | ||
| Q2 25 | $147.7M | $188.2M | ||
| Q1 25 | $123.9M | $197.2M | ||
| Q4 24 | $153.6M | $241.0M | ||
| Q3 24 | $139.0M | $225.5M | ||
| Q2 24 | $151.2M | $256.0M | ||
| Q1 24 | $129.5M | $263.4M |
净利润BVSRILY
| Q4 25 | $14.8M | $90.3M | ||
| Q3 25 | $3.2M | $91.1M | ||
| Q2 25 | $7.5M | $139.5M | ||
| Q1 25 | $-2.6M | $-10.0M | ||
| Q4 24 | $-388.0K | $-5.6M | ||
| Q3 24 | $-5.2M | $-284.4M | ||
| Q2 24 | $-25.7M | $-433.6M | ||
| Q1 24 | $-4.9M | $-49.2M |
毛利率BVSRILY
| Q4 25 | 68.9% | 79.5% | ||
| Q3 25 | 68.0% | 83.7% | ||
| Q2 25 | 69.1% | 81.3% | ||
| Q1 25 | 67.0% | 81.4% | ||
| Q4 24 | 66.8% | 79.8% | ||
| Q3 24 | 67.3% | 82.1% | ||
| Q2 24 | 68.5% | 84.5% | ||
| Q1 24 | 68.3% | 85.3% |
营业利润率BVSRILY
| Q4 25 | 12.3% | 32.3% | ||
| Q3 25 | 8.1% | 30.4% | ||
| Q2 25 | 12.4% | 5.7% | ||
| Q1 25 | 3.9% | -31.2% | ||
| Q4 24 | 5.0% | -69.2% | ||
| Q3 24 | 2.6% | -36.4% | ||
| Q2 24 | -20.8% | -90.8% | ||
| Q1 24 | 3.8% | -6.1% |
净利率BVSRILY
| Q4 25 | 9.3% | 47.9% | ||
| Q3 25 | 2.3% | 42.3% | ||
| Q2 25 | 5.1% | 74.1% | ||
| Q1 25 | -2.1% | -5.1% | ||
| Q4 24 | -0.3% | -2.3% | ||
| Q3 24 | -3.7% | -126.1% | ||
| Q2 24 | -17.0% | -169.4% | ||
| Q1 24 | -3.8% | -18.7% |
每股收益（稀释后）BVSRILY
| Q4 25 | $0.21 | $2.78 | ||
| Q3 25 | $0.05 | $2.91 | ||
| Q2 25 | $0.11 | $4.50 | ||
| Q1 25 | $-0.04 | $-0.39 | ||
| Q4 24 | $0.00 | $-0.01 | ||
| Q3 24 | $-0.08 | $-9.39 | ||
| Q2 24 | $-0.40 | $-14.35 | ||
| Q1 24 | $-0.08 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $51.2M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $184.1M | $-171.5M |
| 总资产 | $683.6M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BVSRILY
| Q4 25 | $51.2M | $226.6M | ||
| Q3 25 | $42.2M | $184.2M | ||
| Q2 25 | $32.9M | $267.4M | ||
| Q1 25 | $22.8M | $138.3M | ||
| Q4 24 | $41.6M | $146.9M | ||
| Q3 24 | $43.1M | $159.2M | ||
| Q2 24 | $32.0M | $236.9M | ||
| Q1 24 | $25.2M | $190.7M |
总债务BVSRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BVSRILY
| Q4 25 | $184.1M | $-171.5M | ||
| Q3 25 | $166.1M | $-260.5M | ||
| Q2 25 | $161.2M | $-351.7M | ||
| Q1 25 | $148.1M | $-496.8M | ||
| Q4 24 | $147.9M | $-488.2M | ||
| Q3 24 | $148.7M | $-497.6M | ||
| Q2 24 | $150.9M | $-218.3M | ||
| Q1 24 | $171.3M | $228.4M |
总资产BVSRILY
| Q4 25 | $683.6M | $1.7B | ||
| Q3 25 | $701.6M | $1.7B | ||
| Q2 25 | $706.8M | $1.5B | ||
| Q1 25 | $691.4M | $1.5B | ||
| Q4 24 | $728.0M | $1.8B | ||
| Q3 24 | $769.5M | $2.2B | ||
| Q2 24 | $792.2M | $3.2B | ||
| Q1 24 | $794.2M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.0M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $37.4M | — |
| 自由现金流率自由现金流/营收 | 23.7% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | 2.57× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $72.1M | — |
8季度趋势，按日历期对齐
经营现金流BVSRILY
| Q4 25 | $38.0M | $26.2M | ||
| Q3 25 | $30.1M | $-60.6M | ||
| Q2 25 | $25.9M | $-25.6M | ||
| Q1 25 | $-19.3M | $184.0K | ||
| Q4 24 | $19.3M | $-2.7M | ||
| Q3 24 | $10.3M | $19.5M | ||
| Q2 24 | $15.2M | $111.5M | ||
| Q1 24 | $-6.0M | $135.4M |
自由现金流BVSRILY
| Q4 25 | $37.4M | — | ||
| Q3 25 | $29.6M | — | ||
| Q2 25 | $25.3M | — | ||
| Q1 25 | $-20.2M | — | ||
| Q4 24 | $18.7M | — | ||
| Q3 24 | $10.3M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $-6.3M | — |
自由现金流率BVSRILY
| Q4 25 | 23.7% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 17.1% | — | ||
| Q1 25 | -16.3% | — | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 10.0% | — | ||
| Q1 24 | -4.9% | — |
资本支出强度BVSRILY
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.2% | — |
现金转化率BVSRILY
| Q4 25 | 2.57× | 0.29× | ||
| Q3 25 | 9.54× | -0.66× | ||
| Q2 25 | 3.48× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BVS
| Pain Treatments | $71.1M | 45% |
| Surgical Solutions | $48.9M | 31% |
| Restorative Therapies | $19.5M | 12% |
| Other | $18.4M | 12% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
